10:13 AM
 | 
Oct 26, 2018
 |  BC Week In Review  |  Company News  |  Deals

Alexion moves into RNAi with Dicerna deal

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) entered into the RNAi field with a deal with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies for complement-mediated diseases. Alexion also reported higher-than-expected revenues and sales of Soliris eculizumab in its 3Q18 earnings report released on Oct. 24.

Alexion gains exclusive worldwide rights to two preclinical RNAi molecules developed using Dicerna's GalXC technology, and an option to license two additional GalXC RNAi molecules. Dicerna will receive $22 million up front and Alexion will invest $15 million in the RNAi company. Dicerna is eligible for up to $10 million in option fees for each of the two additional candidates, up to $105...

Read the full 518 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >